We are Core-Oli-T AB
Core-Oli-T AB is a Swedish biotech company founded at Linnaeus University with a clear mission — to revolutionize the early detection of neurodegenerative diseases, starting with Parkinson’s disease. Parkinson’s affects over 10 million people worldwide and remains the fastest-growing neurological disorder. Current diagnostic methods often identify the disease only after irreversible nerve damage has occurred.
At Core-Oli-T, we combine advanced sensor technology, materials chemistry, and biomedical research to develop innovative biomarker-based diagnostic tools. Our goal is to enable earlier and more accurate diagnosis, empowering physicians to take action sooner — improving treatment outcomes and quality of life for patients around the world.
Driving innovation in life science to improve Parkinson’s disease diagnosis
Here we highlight challenges in Parkinson’s disease and how our monoclonal antibodies provide effective support in diagnostics and treatment.
Precision antibodies for early diagnostics
Our monoclonal antibodies enable rapid and accurate identification of Parkinson’s disease for better patient care.
Optimized therapy with directed antibodies
Our technology reduces treatment barriers and improves patient outcomes with tailored solutions.
Support to research development
We turn complex research challenges into opportunities with reliable antibodies and expertise.